Skip to content

Early monitoring of intravenous thrombolysis in acute ischemic stroke based on wearable smart monitoring device: a prospective, multicenter, observational registry cohort study

Early monitoring of intravenous thrombolysis in acute ischemic stroke based on wearable smart monitoring device: a prospective, multicenter, observational registry cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069512
Enrollment
Unknown
Registered
2023-03-20
Start date
2023-03-20
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Wearable monitoring group:After the patient was initially judged as a stroke patient by emergency triage and decided to use wearable monitoring devices by the doctor, he began to use intelligent monit
Conventional traditional monitoring group:After the patient was initially diagnosed as a stroke patient by emergency triage and the doctor decided to use traditional monitoring equipment, the patient

Sponsors

Xuanwu Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Age =18 years old; (2) Meet the diagnostic criteria of acute ischemic stroke in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 and meet the indications of intravenous thrombolysis; (3) Intravenous thrombolysis was given within 4.5 hours of onset; (4) The subject or legal agent can sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) The subject or legal agent is unable to cooperate in completing the follow-up; (2) Patients terminated by intravenous thrombolysis; (3) Bridging or endovascular thrombectomy; (4) Patients transferred to our hospital after intravenous thrombolysis in other hospitals; (5) The patient is complicated with severe systemic diseases, and the expected survival time is less than 6 months; (6) Patients who have participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Proportion of mRS scale score 0-1;

Secondary

MeasureTime frame
Readmission;Proportion of mRS scale score 0-2;stroke Recurrence;Cardiovascular events;The quality of life;All-cause death;Incidence of symptomatic intracranial hemorrhage and symptomatic intracranial hemorrhage;

Countries

China

Contacts

Public ContactChangHong

Xuanwu Hospital of Capital Medical University

changhong19791111@126.com13701034090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026